The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thank you cadellin
don't go in then but if you do look at cash shells and reverse takeovers ( what they mean) before you do. ( youtube is good for this )
i remember pmg it was ashell when tom cross bought a stake went from 1p to 80odd pence just on that.its all about the potential and this has plenty its anybodies guess where this will end up
What are people’s honest opinions on the value of him joining the board? In MCAP/SP terms? I’ve been spiked so many times and if I come in here I don’t want to be spiked but think there’s more behind this mega rise
Well done MAFs . It was a dog with no legs and is now a dachshund with little ones . Let’s hope they are not too little to climb the stairs tomorrow
Can’t believe I went back on this after suffering in the valentine day massacre . But it’s a strange market at the moment and strange things are happening . Bet the FDA would pass it now in this climate
Thanks all going to do some research and reading tonight, just looked back at share price as a couple of years back it was trading at 30p’s imagine if it gets back there and more!
Sam12345 how long have you got read all the rns would take some time. Basically the company is doing a reversed takeover. Today appointed a new reshuffled board to take it forward using their targeted formula using inhalers.
Not everyday do you see a Share rise like this, so it forced me to research a little.
The appointment of Chris Wardhaugh as stated in the RNS is critical for this to succeed. For those who do not know him, research his achievements. Some of them include:
Cheif Business Officer for MGB Biopharma - which is a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance.
Why is this important? - because Iclaprim which is in its phase III is an anti-biotic that treats skin diseases - it has reached 'Orphan status' in the U.S which is pretty big.
So why was he appointed by MGB Biopharma? - because they were in preparing to start PHASE II trial of MGB-BP-3 to assess the initial cure and sustained cure rates in the treatment of Clostridium difficile-associated diarrhoea (CDAD).
Why is this important - because Iclaprim is in the PHASE II/III stages and this guy has the experience and knowledge.
So what happened to that anti-infective medication - The company suddenly goes on to succeeding and getting it approved.
To cut the story short, and to save the best to last, the guy specialises in Company acquisitions and has bloody overseen the launch of 8 pharmaceutical products around the world. So everyone is in good hands. In fact, I might even join you guys in this.
Full info:
CHRIS WARDHAUGH has over 25 years of experience in the Life Science Sector including being Senior Director of Global Partnering of Quintiles and Head of Business Development and Operations Director of Prostrakan, among others. Most recently, Chris has been Senior Executive Advisor for Nanogenics, Senior Advisor for Clyde Biosciences and the Founder of Sercader Limited and previously he was Chief Operating Officer and President of Clyde Biosciences.
Mr Wardhaugh’s has significant transaction experience, including company acquisitions, funding rounds, market entries and IPOs. He has also overseen the launch of 8 pharmaceutical products (such as Tostran, Abstral, Rectogesic) in the USA, UK, Germany, France, Italy, Spain, The Netherlands, Belgium, and others.
https://www.mgb-biopharma.com/mgb-biopharma-expands-management-team-with-appointment-of-chris-wardhaugh-as-chief-business-officer/
Money munch what’s your target price here?
Will do money munch thanks
Just buy in as you can see from April onwards the price has gradually risen, the longer you wait he higher you'll have to pay for the sp. I mean look at GDR now, we'll be there eventually once big news lands.
Click on my username sam, and see what i've posted today on this thread, a bit or repetition in places to keep the reasons why in view, but research and speculation which might give you an idea why the sp has flown today. Gl ;-)
Why the rise here? Gut tells me pump and dump but I’d love to hear the genuine reason if there is one
Let -it -roll
I was thinking the same hmmmm my little gray cells tells me it is a close call for sure. But nevertheless a bit of fun for the isolated nations.
Almost got caught napping and was a bit late to the party. But have still managed a bag today.
RTO can sometimes not be great for existing shareholders. But this potential one would seem mutually beneficial.
I really can't call tomorrow. But am still in atm. I'm trying to rack my brains when I last saw a share go up so much in 1 day. I think it was the dot com boom lol
If you want to know what know that you dont know, invest your time and scroll back to read info provided by intelligent people who find time to research. Covid19 slogan...test,test,test...
Trading slogan, research, research, research DYOR.
Why it went up? :]
Lol, cheers eviking, research and speculation, fingers firmly crossed for a positive outcome. Gl ;-)
What sort of question is this?
Do you want a biased answer; yes, invest everything you can tomorrow.
Do you want an unbiased answer; yes, invest everything you can tomorrow.
Seriously...
Missthepenny thanks all in the rns to see. Delisted on the nas
Correct, it is not live price on Nasdaq. My bad, I was searching for MTFB on IG app and found Nasdaq one instead of LON listing.
Since then, there was the RNS on 30/09/2020, about the Hercules Loan agreement.
Numerous 'price monitoring' activity and Institutional investors decreasing their holding
Furthermore, please see this video; https://www.youtube.com/watch?v=p3HQzzZQhpI
24th May 2019 - 1:10 This is a video of Graham Lumsden talking about Iclaprim (Motif bio) and LMS611 (Lamellasome) Working together to treat Staphylococcus Aureus pneumonia in cystic fibrosis. Iclaprim already have an 'Orphan status' in USA.
RNS Today (04/04/2020):
Appointment of Chris Wardhaugh is appointed as a Non-Executive Director;
Chris is currently a Non-Executive Director of Altair Medical Limited and Lamellar Biomedical Limited, both based in Scotland. Chris is also Chief Business Officer of MGB Biopharma Limited, a clinical-stage antibiotic company and is the founder of Sercader Limited, a life sciences advisory firm.
Chris has over 28 years' experience in life sciences with international experience across large and small companies, all stages of development and commercialisation of companies including preclinical and clinical development, product launches throughout Europe and the United States, M&A and corporate development. Chris has an impressive transaction history working on deals including product licensing, IPOs and both Angel and VC investments.
In the red on the Nasdaq you say? That's even more remarkable considering its already been delisted over there.
Try again.
- 24/10/2019; U.S. Army-funded research project to Evaluate Iclaprim. The Company has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology.
The aerosol technology allows delivery of antibiotics painlessly and rapidly into skin and soft tissue with low-pressure and focused delivery. The research is being funded through a grant from the U.S. Department of Defense - Congressionally Directed Military Infectious Diseases Research Program to evaluate the potential of using such a drug-device combination for wound care and to prevent and treat wound infections on the battlefield. The work will be led by Dr. Daniel Zurawski,
David Huang, M.D., Ph.D., Chief Medical Officer of Motif Bio, said: "When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible. The data generated from Dr. Zurawski's research will be important in understanding whether iclaprim delivered locally could play a role in treating battlefield wound infections.”
In March 2020 a paper was released that compared PHASE 3 REVIVE of the safety and efficacy of Iclaprim vs Vancomycin for treatment of acute bacterial skin and skin structure infections.
Results: Results. In REVIVE-1, ECR was 83.5?% with iclaprim versus 79.7?% with vancomycin (treatment difference 3.77%, 95?%?CI -4.50%, 12.04%). In REVIVE-2, ECR was 82.7?% with iclaprim versus 76.3?% with vancomycin (treatment difference 6.38%, 95?%?CI -3.35%, 16.12%). In the pooled dataset, iclaprim had similar ECR rates compared with vancomycin among wound infection patients (83.2?% vs 78.2?%) with a treatment difference of 5.01?% (95?% CI -1.29%, 11.32%). The safety profile was similar in iclaprim- and vancomycin-treated patients, except for a higher incidence of diarrhea with vancomycin (n=17) compared with iclaprim (n=6) and fatigue with iclaprim (n=17) compared with vancomycin (n=8).
Conclusion. Based on early clinical response, iclaprim achieved non-inferiority to vancomycin with a similar safety profile in patients with wound infections suspected or confirmed as caused by Gram-positive pathogens. Iclaprim may be a valuable treatment option for wound infections.
-10/10/2019; As disclosed in the announcement on September 30, 2019, the minutes confirm that a single well-designed adequate and well-controlled Phase III clinical trial demonstrating safety and efficacy of iclaprim in patients with HABP, including VABP, along with data on potential mechanisms of hepatic injury, would enable submission of a New Drug Application for approval by FDA. It would take several years to enrol and complete a HABP/VABP Phase III trial and the cost is expected to be tens of millions of dollars.
The Company continues to believe that the most efficient way to generate future value from iclaprim is for a partner or other entity with a lower cost of capital to complete the HABP/VABP Phase III trial and commercialise the asset globally.
Dr. Graham Lumsden, Chief Executive Officer, said: "We now have confirmation of what will be required to progress iclaprim towards a potential approval. The Company is working hard to find a partner or other entity to complete the HABP/VABP Phase III trial, commercialise iclaprim and ensure the best outcome for shareholders in Motif Bio."